MedPath
NMPA Approval

Riluzole Oral Suspension

国药准字HJ20220053

May 31, 2022

Drug Information

利鲁唑口服混悬液

口服混悬剂

300ml:1.5g

化学药品

May 31, 2022

May 30, 2027

Company Information

Applicant Company

Italfarmaco S A

San Rafael, 3 28108 Alcobendas (Madrid) Spain

Manufacturing Company

Italfarmaco S A

San Rafael, 3 28108 Alcobendas (Madrid) Spain

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

利鲁唑口服混悬液 - NMPA 批准文号 | MedPath